Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Feb 29, 2024 | (Q3)Nov 30, 2023 | (Q2)Aug 31, 2023 | (Q1)May 31, 2023 | (FY)Feb 28, 2023 | (Q4)Feb 28, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -498.33K | -1.87M | -853.68K | 29.02%-4.24M | 3,449.25%1.84M | -236.77%-996.14K | 67.37%-1.12M | -13.33%-3.65M | -154.97%-5.97M | -102.88%-54.84K |
| Net income from continuing operations | ---1.97M | ---2.2M | ---2.51M | 19.87%-10.5M | 89.58%-684.64K | 6.83%-1.34M | -8.39%-3.31M | -28.32%-2.62M | -58.67%-13.1M | -149.92%-6.57M |
| Operating gains losses | --180.83K | --27.71K | --10.54K | 21.42%252.5K | 88.09%-25.34K | -102.17%-17.87K | 217.85%514.33K | 106.36%70.45K | 188.41%207.96K | -431.99%-212.73K |
| Depreciation and amortization | --0 | --0 | --0 | -76.49%50.06K | -4.69%145.45K | -406.13%-64.77K | 223.93%76.94K | 211.23%48.02K | 724.71%212.94K | 491.01%152.6K |
| Asset impairment expenditure | ---- | ---- | ---- | -11.83%3.28M | ---- | ---- | ---- | ---- | --3.72M | ---- |
| Unrealized gains and losses of investment securities | --200.1K | ---182.28K | --5.35K | 137.03%542.9K | 125.98%9.34K | 1,144.36%208.87K | 267.36%312.25K | 333.70%867.39K | -44.81%229.05K | -120.54%-35.95K |
| Remuneration paid in stock | --726.93K | --728.21K | --684.49K | -39.18%1.7M | -205.34%-666.92K | -19.44%546.12K | -13.73%726.19K | 13.50%730.99K | 0.29%2.8M | -3.93%633.11K |
| Other non cashItems | --134.5K | --142.79K | --82.19K | 3,620.06%266.99K | -50.75%792 | -40.29%999 | -2,586.94%-45.31K | 2,211.43%47.94K | 198.17%7.18K | --1.61K |
| Change In working capital | --227.65K | ---388.5K | --870.8K | 438.29%162.89K | 35.75%3.06M | -150.05%-330.94K | 169.06%609.89K | -34.69%-2.8M | -101.65%-48.15K | -37.58%2.25M |
| -Change in prepaid assets | --18.98K | --530.7K | ---87.17K | 92.49%-3.67K | -169.28%-279.04K | 71.55%-250.23K | 115.85%62.66K | -48.98%420.11K | 89.86%-48.85K | 187.32%402.74K |
| -Change in payables and accrued expense | --208.67K | ---919.2K | --957.97K | 23,659.77%166.56K | 80.39%3.34M | -105.24%-80.71K | 212.19%547.23K | -10.95%-3.22M | -99.98%701 | -54.55%1.85M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | ---498.33K | ---1.87M | ---853.68K | 29.02%-4.24M | 3,449.25%1.84M | -236.77%-996.14K | 67.37%-1.12M | -13.33%-3.65M | -154.97%-5.97M | -102.88%-54.84K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 45.03M | -57.24M | -6.87M | 13.89%-25.41M | -31.94%-8.59M | -17.07%-9.97M | 7.81%-5.03M | 12.03%-7.93M | -23.98%-29.5M | 7.61%-6.51M |
| Net PPE purchase and sale | ---141.83K | ---1.33K | ---224.32K | 98.97%-23.75K | -248.84%-502.63K | -50.64%-2.54M | 100.41%2.65K | 94.63%-16.08K | -572.51%-2.3M | 414.01%337.69K |
| Net investment purchase and sale | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---369.51K | ---- |
| Net other investing changes | ---4.83M | ---7.24M | ---6.65M | 5.41%-25.38M | -24.83%-8.09M | -8.80%-7.43M | -4.79%-5.03M | 9.19%-7.92M | -14.40%-26.83M | 6.64%-6.48M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --45.03M | ---57.24M | ---6.87M | 13.89%-25.41M | -31.94%-8.59M | -17.07%-9.97M | 7.81%-5.03M | 12.03%-7.93M | -23.98%-29.5M | 7.61%-6.51M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 29.19K | 29.24M | 48.66M | -38.12%37.56M | -100.04%-17.71K | 173.21%56.02K | 9,397.74%1.49M | -98.00%254.88K | 22.15%60.7M | 4,294.35%48.07M |
| Net issuance payments of debt | --0 | --0 | --0 | 18.75%-54.01K | -1.59%-17.71K | -8.37%-17.69K | -9.92%-17.67K | -7.06%-17.82K | -274.11%-66.48K | 1.89%-17.43K |
| Net common stock issuance | --0 | --28.41M | --51.75M | -26.09%35.09M | --0 | -14.13%-98.49K | --0 | ---75.3K | -2.42%47.48M | --47.56M |
| Proceeds from stock option exercised by employees | --29.19K | --875.05K | --0 | -65.21%4.69M | --0 | 559.77%172.2K | --1.51M | -97.27%348K | 333.08%13.49M | -34.61%727K |
| Net other financing activities | --0 | ---38.76K | ---3.09M | -986.00%-2.17M | ---- | ---- | ---- | ---- | 90.30%-199.81K | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --29.19K | --29.24M | --48.66M | -38.12%37.56M | -100.04%-17.71K | 173.21%56.02K | 9,397.74%1.49M | -98.00%254.88K | 22.15%60.7M | 4,294.35%48.07M |
| Net cash flow | ||||||||||
| Beginning cash position | --55.81M | --85.68M | --44.74M | -18.65%36.83M | 50.39%43.61M | 47.90%54.52M | 29.32%59.17M | 55.71%70.5M | 108.41%45.28M | -41.22%28.99M |
| Current changes in cash | --44.56M | ---29.87M | --40.93M | -68.62%7.91M | -116.32%-6.78M | -38.73%-10.91M | 47.69%-4.65M | -2,462.11%-11.33M | 7.10%25.22M | 1,124.98%41.51M |
| End cash Position | --100.36M | --55.81M | --85.68M | -36.53%44.74M | -47.76%36.83M | 50.39%43.61M | 47.90%54.52M | 29.32%59.17M | 55.71%70.5M | 55.71%70.5M |
| Free cash from | ---640.16K | ---1.87M | ---1.08M | 48.48%-4.26M | 371.62%1.33M | -269.42%-3.53M | 72.67%-1.11M | -4.15%-3.67M | -208.19%-8.27M | -84.28%282.86K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.